Global Bile Duct Cancer Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: July 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Bile Duct Cancer Market was valued at $4.2 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 8.6% CAGR, to an estimated market size of $6.4 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global bile duct cancer (cholangiocarcinoma) market encompasses the pharmaceutical and diagnostic landscape for malignancies arising in the biliary tree, including intrahepatic and extrahepatic (perihilar and distal) subtypes. The scope includes targeted therapies, immunotherapies, and chemotherapy, as well as advanced diagnostic procedures like ERCP and molecular profiling, while excluding non-biliary liver cancers.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Bile Duct Cancer Market in the period 2025-30:
- A decisive shift is occurring from conventional cytotoxic regimens toward precision medicine and molecularly targeted agents like FGFR and IDH1 inhibitors.
- The integration of checkpoint inhibitors such as pembrolizumab and durvalumab into first-line treatment is significantly improving survival outcomes.
- Rising global incidence rates are linked to an aging population and the increasing prevalence of metabolic risk factors like obesity and chronic liver disease.
- Widespread adoption of Next-Generation Sequencing (NGS) and liquid biopsies is enabling earlier detection and more accurate biomarker-driven therapy selection.
- Accelerated regulatory approvals and orphan drug designations are catalyzing heavy pharmaceutical investment in robust clinical trial pipelines.
- The Asia-Pacific region is emerging as a high-growth hub due to endemic disease prevalence and rapid expansion of specialized oncology infrastructure.
- High economic burden and fragmented reimbursement for novel, high-cost therapies remain significant barriers to patient access in low-income regions.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Targeted Therapy
- Chemotherapy
- Immunotherapy
- Other (Surgery and Radiation)